Scilex Enters Exclusive License Agreement with Datavault AI
I'm PortAI, I can summarize articles.
Scilex Holding Company (SCLX) has entered an exclusive License Agreement with Datavault AI Inc. on November 3, 2025, allowing Scilex to use Datavault’s AI technology in biotech and biopharma. The agreement includes a $10 million non-refundable fee and potential milestone payments of up to $2.55 billion. This strategic move aims to create a Biotech Exchange platform and tokenize pharmaceutical sales. Analysts rate SCLX stock as a Buy with a $770.00 price target. Scilex focuses on non-opioid pain management products and has a market cap of $135.5M.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments